XML 62 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements (Tables)
12 Months Ended
Dec. 29, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Revenues Under Collaboration Agreement
Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Royalties accruing to GSK
$
12,413

 
$
4,334

 
$
1,029

Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
Milestones achieved
$
45,000

 
$
20,000

Amortization of upfront payments and deferred milestone
18,531

 
13,284

Royalty revenue
3,831

 
175

Development cost reimbursements
4,417

 

Product supply agreement revenue
6,390

 
1,612

Cost of supplied product
(6,390
)
 
(1,555
)
Royalty payable to GSK on net sales by Ipsen
(1,987
)
 
(264
)
Collaboration revenues under the collaboration agreement with Ipsen
$
69,792

 
$
33,252

Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Collaboration revenues:
 
 
 
 
 
Royalty revenues on ex-U.S. sales of COTELLIC
$
6,398

 
$
2,827

 
$
14

U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses
$
(2,140
)
 
$
8,771

 
$
(16,600
)
Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):
 
Year Ended December 31, 2017
Amortization of upfront payment
$
10,377

Development cost reimbursements
4,320

Product supply agreement revenue
82

Collaboration revenues under the collaboration agreement with Takeda
$
14,779